alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › repurposing

repurposing

234 studies tagged repurposing, dated 1977-11-01 to 2026-10-25. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Integrated Transcriptomic and Structural Prioritization of Sulforaphane Targets in Neurodegeneration: A Multi-Dataset In Silico Study 2026-10-25
  2. Natural Sesquiterpenoids from Laggera pterodonta as bioactive Acetylcholinesterase Inhibitors: Insights from DFT, Molecular Docking, and ADMET Profiling 2026-10-20
  3. DNA-Encoded Library-Guided Discovery of a First-in-Class Molecular Glue of the NOS1AP-SCRIB Complex in Alzheimer’s Disease Patient-Derived Neurons 2026-10-18

Studies

234 studies carry this tag.

Date range

1977 to 2026

Top journals

  • Research Square 9
  • Journal of medicinal chemistry 7
  • International journal of molecular sciences 6
  • Journal of Alzheimer's disease : JAD 6
  • Nature reviews. Drug discovery 6

154 journals in all.

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. BACE-1 Inhibitors: From Recent Single-Target Molecules to Multitarget Compounds for Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of medicinal chemistry 2017-08-08 Treatments

    The amyloid hypothesis has long been the central dogma in drug discovery for Alzheimer's disease (AD), leading to many small-molecule and biological drug candidates.

  2. Metformin and Its Sulfenamide Prodrugs Inhibit Human Cholinesterase Activity

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Oxidative medicine and cellular longevity 2017-07-09 Drug development

    The results of epidemiological and pathophysiological studies suggest that type 2 diabetes mellitus (T2DM) may predispose to Alzheimer's disease (AD).

  3. Assessing the binding of cholinesterase inhibitors by docking and molecular dynamics studies

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Journal of molecular graphics & modelling 2017-06-29 Treatments

    In this report we assessed by docking and molecular dynamics the binding mechanisms of three FDA-approved Alzheimer drugs, inhibitors of the enzyme acetylcholinesterase (AChE): donepezil, galantamine and rivastigmine.

  4. Drug Repositioning for Alzheimer's Disease Based on Systematic 'omics' Data Mining

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. PloS one 2016-12-22 Drug development

    Traditional drug development for Alzheimer's disease (AD) is costly, time consuming and burdened by a very low success rate.

  5. Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Frontiers in neuroscience 2016-05-25 Treatments

    Although its etiology is not completely known, several factors including deficits of acetylcholine, β-amyloid deposits, τ-protein phosphorylation, oxidative stress, and neuroinflammation are considered to play significant roles in the pathophysiology of this disease.

  6. One for All? Hitting Multiple Alzheimer's Disease Targets with One Drug

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Frontiers in neuroscience 2016-04-25 Drug development

    HIGHLIGHTS Many AD target combinations are being explored for multi-target drug design.

  7. Amidated and Ibuprofen-Conjugated Kyotorphins Promote Neuronal Rescue and Memory Recovery in Cerebral Hypoperfusion Dementia Model

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Frontiers in Aging Neuroscience 2016-01-26 Biomarkers

    Chronic brain ischemia is a prominent risk factor for neurological dysfunction and progression for dementias, including Alzheimer's disease (AD).

  8. Effect of Donepezil, Tacrine, Galantamine and Rivastigmine on Acetylcholinesterase Inhibition in Dugesia tigrina

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Molecules (Basel, Switzerland) 2016-01-11 Treatments

    Dugesia tigrina is a non-parasitic platyhelminth, which has been recently utilized in pharmacological models, regarding the nervous system, as it presents a wide sensitivity to drugs.

  9. Therapeutic strategies for Alzheimer's disease in clinical trials

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Pharmacological reports : PR 2015-08-05 Treatments

    Alzheimer's disease (AD) is considered to be the most common cause of dementia and is an incurable, progressive neurodegenerative disorder.

  10. Nanotechnology-based drug delivery systems for the treatment of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 67 out of 100. International journal of nanomedicine 2015-08-04 Treatments

    Alzheimer's disease is a neurological disorder that results in cognitive and behavioral impairment.

  11. HMG-CoA Reductase Inhibitors Bind to PPARα to Upregulate Neurotrophin Expression in the Brain and Improve Memory in Mice

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Cell metabolism 2015-06-25 Drug development

    Neurotrophins are important for neuronal health and function.

  12. Checks and balances on cholinergic signaling in brain and body function

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Trends in neurosciences 2015-06-20 Risk factors

    A century after the discovery of acetylcholine (ACh), we recognize both ACh receptors, transporters, and synthesizing and degrading enzymes and regulators of their expression as contributors to cognition, metabolism, and immunity.

  13. The human CHRNA7 and CHRFAM7A genes: A review of the genetics, regulation, and function

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neuropharmacology 2015-02-19 Genetics

    The human α7 neuronal nicotinic acetylcholine receptor gene (CHRNA7) is ubiquitously expressed in both the central nervous system and in the periphery.

  14. Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Current medicinal chemistry 2015-01-01 Treatments

    Alzheimer's disease (AD) is a complex and progressive neurodegenerative disorder.

  15. Medical genetics-based drug repurposing for Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Brain research bulletin 2014-11-22 Drug development

    Alzheimer's disease (AD) is a disease that threatens the elderly.

  16. Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Expert opinion on drug safety 2014-06-01 Treatments

    Patients diagnosed with AD still mostly benefit from four compounds to significantly improve cognition functions and overall health and help manage other symptoms or even prolong the symptom-free period.

  17. Differential effects of angiotensin II receptor blockers on Aβ generation

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Neuroscience letters 2014-03-27 Biomarkers

    Angiotensin II receptor blockers (ARBs) are widely prescribed for the medication of systemic hypertension and congestive heart failure.

  18. Transition-metal-substituted polyoxometalate derivatives as functional anti-amyloid agents for Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Nature communications 2014-03-04 Treatments

    Inhibitions of amyloid β (Aβ) aggregation and Aβ-haem peroxidase-like activity have received much attention because these two symptoms can be the primary targets of therapeutic strategies for Alzheimer's disease (AD).

  19. Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2014-02-01 Drug development

    Traumatic brain injury (TBI), either as an isolated injury or in conjunction with other injuries, is an increasingly common event.

  20. Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Neurotoxicity research 2013-05-09 Treatments

    This review describes the preclinical mechanisms that may underlie the increased therapeutic benefit of combination therapy-with the N-methyl-D-aspartate receptor antagonist, memantine, and an acetylcholinesterase inhibitor (AChEI)-for the treatment of Alzheimer's disease (AD).

  21. Acetylcholinesterase inhibitors: pharmacology and toxicology

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Current neuropharmacology 2013-05-01 Treatments

    Acetylcholinesterase is involved in the termination of impulse transmission by rapid hydrolysis of the neurotransmitter acetylcholine in numerous cholinergic pathways in the central and peripheral nervous systems.

  22. A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. The primary care companion for CNS disorders 2013-03-07 Treatments

    AChE-selective inhibitors and a dual AChE and BuChE inhibitor demonstrate symptomatic efficacy in AD.

  23. A review on cholinesterase inhibitors for Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Archives of pharmacal research 2013-02-24 Treatments

    Alzheimer's disease (AD), a progressive neurodegenerative disorder, is characterized by the deficits in the cholinergic system and deposition of beta amyloid (Aβ) in the form of neurofibrillary tangles and amyloid plaques.

  24. The promise of N-acetylcysteine in neuropsychiatry

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Trends in pharmacological sciences 2013-01-29 Prevention and risk

    N-Acetylcysteine (NAC) targets a diverse array of factors germane to the pathophysiology of multiple neuropsychiatric disorders including glutamatergic transmission, the antioxidant glutathione, neurotrophins, apoptosis, mitochondrial function, and inflammatory pathways.

  25. Galantamine potentiates the neuroprotective effect of memantine against NMDA-induced excitotoxicity

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Brain and behavior 2013-01-11 Treatments

    The combination of memantine, an N-methyl-d-aspartate (NMDA) receptor antagonist, with an acetylcholinesterase inhibitor (AChEI) is the current standard of care in Alzheimer's disease (AD).

  26. Current and future treatments for Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Therapeutic advances in neurological disorders 2013-01-01 Treatments

    Alzheimer's dementia (AD) is increasingly being recognized as one of the most important medical and social problems in older people in industrialized and non-industrialized nations.

  27. Discovering new treatments for Alzheimer's disease by repurposing approved medications

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Current topics in medicinal chemistry 2013-01-01 Drug development

    Alzheimer's disease (AD) is the most common cause of dementia and a major cause of morbidity and mortality.

  28. Glutamate system, amyloid ß peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of psychiatry & neuroscience : JPN 2013-01-01 Treatments

    Alzheimer disease is the most prevalent form of dementia globally and is characterized premortem by a gradual memory loss and deterioration of higher cognitive functions and postmortem by neuritic plaques containing amyloid ß peptide and neurofibrillary tangles containing phospho-tau protein.

  29. Neuroactive insecticides: targets, selectivity, resistance, and secondary effects

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Annual review of entomology 2013-01-01 Risk factors

    Neuroactive insecticides are the principal means of protecting crops, people, livestock, and pets from pest insect attack and disease transmission.

  30. Structures of human acetylcholinesterase in complex with pharmacologically important ligands

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of medicinal chemistry 2012-11-12 Treatments

    Human acetylcholinesterase (AChE) is a significant target for therapeutic drugs.

  31. Drug repositioning for Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 64 out of 100. Nature reviews. Drug discovery 2012-11-01 Drug development

    Existing drugs for Alzheimer's disease provide symptomatic benefit for up to 12 months, but there are no approved disease-modifying therapies.

  32. Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of medicinal chemistry 2012-10-08 Down syndrome and Alzheimer's

    DYRKs (dual specificity, tyrosine phosphorylation regulated kinases) and CLKs (cdc2-like kinases) are implicated in the onset and development of Alzheimer's disease and Down syndrome.

  33. Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. ACS chemical neuroscience 2012-08-28 Down syndrome and Alzheimer's

    With 24.3 million people affected in 2005 and an estimated rise to 42.3 million in 2020, dementia is currently a leading unmet medical need and costly burden on public health.

  34. N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Current Alzheimer research 2012-07-01 Treatments

    Memantine, a partial antagonist of N-methyl-D-aspartate receptor (NMDAR), approved for moderate to severe Alzheimer's disease (AD) treatment within the U.S. and Europe under brand name Namenda (Forest), Axura and Akatinol (Merz), and Ebixa and Abixa (Lundbeck), may have potential in alleviating additional neurological conditions, such as vascular dementia (VD) and Parkinson's disease (PD).

  35. Selective GABA(A) α5 positive allosteric modulators improve cognitive function in aged rats with memory impairment

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neuropharmacology 2012-06-23 Digital health tools

    A condition of excess activity in the hippocampal formation is observed in the aging brain and in conditions that confer additional risk during aging for Alzheimer's disease.

  36. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2012-04-27 Treatments

    The rivastigmine (RHT) loaded chitosan nanoparticles (CS-RHT NPs) were prepared by ionic gelation method to improve the bioavailability and enhance the uptake of RHT to the brain via intranasal (i.n.) delivery.

  37. New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. British journal of clinical pharmacology 2012-04-01 Treatments

    Current approved drug treatments for Alzheimer disease (AD) include cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and the NMDA receptor antagonist memantine.

  38. Functional consequences of repeated organophosphate exposure: potential non-cholinergic mechanisms

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Pharmacology & therapeutics 2012-03-20 Risk factors

    The class of chemicals known as the "organophosphates" (OPs) comprises many of the most common agricultural and commercial pesticides that are used worldwide as well as the highly toxic chemical warfare agents.

  39. New acetylcholinesterase inhibitors for Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. International journal of Alzheimer's disease 2011-12-15 Treatments

    Acetylcholinesterase (AChE) remains a highly viable target for the symptomatic improvement in Alzheimer's disease (AD) because cholinergic deficit is a consistent and early finding in AD.

  40. Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of medicinal chemistry 2011-11-15 Treatments

    A new family of multitarget molecules able to interact with acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), as well as with monoamino oxidase (MAO) A and B, has been synthesized.

  41. Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of cellular physiology 2011-10-01 Prevention and risk

    Glutamate is an essential excitatory neurotransmitter regulating brain functions.

  42. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2011-09-28 Clinical safety

    Glutamate is the primary excitatory neurotransmitter in mammalian brain.

  43. Cholinesterases, a target of pharmacology and toxicology

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 2011-09-01 Treatments

    The crucial role of the cholinesterases in neural transmission makes them a primary target of a large number of cholinesterase-inhibiting drugs and toxins.

  44. Identification of novel functional inhibitors of acid sphingomyelinase

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. PloS one 2011-08-31 Digital health tools

    We describe a hitherto unknown feature for 27 small drug-like molecules, namely functional inhibition of acid sphingomyelinase (ASM).

  45. Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of medicinal chemistry 2011-05-26 Down syndrome and Alzheimer's

    We here report on the synthesis, optimization, and biological characterization of leucettines, a family of kinase inhibitors derived from the marine sponge leucettamine B. Stepwise synthesis of analogues starting from the natural structure, guided by activity testing on eight purified kinases, led to highly potent inhibitors of CLKs and DYRKs, two families of kinases involved in alternative pre-mRNA splicing and Alzheimer's disease/Down syndrome.

  46. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neuropharmacology 2011-05-19 End-of-life care

    Inhibition of phosphodiesterase 9 (PDE9) has been reported to enhance rodent cognitive function and may represent a potential novel approach to improving cognitive dysfunction in Alzheimer's disease.

  47. Assessment of acetylcholinesterase activity using indoxylacetate and comparison with the standard Ellman's method

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. International journal of molecular sciences 2011-04-18 Risk factors

    Assay of acetylcholinesterase (AChE) activity plays an important role in diagnostic, detection of pesticides and nerve agents, in vitro characterization of toxins and drugs including potential treatments for Alzheimer's disease.

  48. Implications for treatment: GABAA receptors in aging, Down syndrome and Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of neurochemistry 2011-03-28 Down syndrome and Alzheimer's

    In addition to progressive dementia, Alzheimer's disease (AD) is characterized by increased incidence of seizure activity.

  49. Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of Alzheimer's disease : JAD 2011-01-01 Drug development

    There is growing evidence to support the hypothesis that statins may act as neuroprotectants in several neuropathological conditions, including Alzheimer's disease.

  50. Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. The Journal of neuroscience : the official journal of the Society for Neuroscience 2010-08-01 Treatments

    Glutamate is the major excitatory neurotransmitter in the brain.

From across this tag

9 of the 234 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.

All topic tags with their study counts